Clinical trial
BrUOG 299: Ixazomib, Oral Metronomic Cyclophosphamide and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study.
NCT02412228 is registered in ClinicalTrials.gov with John L. Reagan as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- BrUOG 299: Ixazomib, Oral Metronomic Cyclophosphamide and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study.
- Lead sponsor
- John L. Reagan
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2015
- Completion date
- November 9, 2023
- Enrollment
- 12 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.